Compound ID | 3415

Update compound information

LptA-OMPTA

Class: Antimicrobial peptide

Agent Type: Semisynthetic; Direct acting;
Spectrum of activity: Gram-negative
Mechanism of action: Lipopolysaccharide synthesis inhibitor. LptA inhibitor
Target Pathogen: Active against Enterobacterales, Klebsiella pneumoniae, and Citrobacter including colistin-resistant strains
Description: Semi-synthetic compound derived from thanatin
Institute where first reported: Spexis AG
Year first mentioned: 2022
Highest development stage: Preclinical
Development status: Experimental
External links:
Citations:
  • https://www.biospace.com/spexis-achieves-first-carb-x-milestone-for-its-thanatin-derivatives-program-and-receives-funding-of-up-to-usd-1-9-million-to-initiate-lead-optimization
  • https://spexisbio.com/platforms/

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.